35 results about "Arteriole smooth muscle" patented technology

To provide an embolic material excision trapping device capable of excising an embolic material in an arteriole or vessel without blocking the blood flow, and further, trapping the material with reliability. A device for removing an embolic material in a lumen in a living body has a long shaft member 1 having a front end and a base end and sending the front end to a distal end of the lumen, a filter member 5 which is provided on the front-end side of the shaft member 1, and contracts linearly inside a catheter for carrying the device while expanding when released into the lumen from the catheter, and a coil member 7 which is provided in the shaft member 1 on the side closer to the base-end side than the filter member 5, and contracts linearly inside the catheter while expanding spirally when released into the lumen from the catheter, where the coil member 7 destroys and traps an embolic material in the lumen, and the filter member 5 traps an liberated piece of the embolic material.

The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and / or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

The invention discloses application of aloperine (ALO) to preparation of a medicine for preventing and curing pulmonary arterial hypertension. A rat pulmonary hypertension model is established to explore the protection effect and mechanism of aloperine on rat pulmonary hypertension. The experiment shows that after the pulmonary hypertension model is established, the aloperine can remarkably improve the hemodynamic parameter, the right ventricular hypertrophy index, the lung index, and the echocardiographic parameter, the pathological injury of pulmonary arterioles is improved, the antioxidant ability of a lung tissue is improved, and the malondialdehyde content and the level of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-2 and NOX-4 in the lung tissue are reduced. The aloperine has the effects of inhibiting the development of pulmonary arterial hypertension, oxidative stress and overexpression of NOX-2 and NOX-4.